Ser50
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser50  -  CAPN2 (human)

Site Information
GTLFQDPsFPAIPSA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 451162

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 2 ) , immunoprecipitation ( 1 ) , mass spectrometry ( 1 ) , mutation of modification site ( 1 , 2 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Relevant cell line - cell type - tissue:
'muscle, smooth'-pulmonary artery ( 1 ) , HEK293T (epithelial) ( 1 ) , NR6WT (fibroblast) ( 2 ) , PASM ( 1 )

Upstream Regulation
Putative in vivo kinases:
ERK1 (human) ( 2 ) , ERK2 (human) ( 2 )
Kinases, in vitro:
ERK1 (human) ( 2 )
Treatments:
5-HT ( 1 ) , endothelin ( 1 ) , fostriecin ( 1 ) , H2O2 ( 1 ) , IL-6 ( 1 ) , PD98059 ( 1 ) , PDGF ( 1 )

Downstream Regulation
Effects of modification on CAPN2:
activity, induced ( 1 )
Effects of modification on biological processes:
cell adhesion, altered ( 2 ) , cell motility, altered ( 2 )

Disease / Diagnostics Relevance
Relevant diseases:
PAH ( 1 )

References 

1

Kovacs L, et al. (2016) Activation of Calpain-2 by Mediators in Pulmonary Vascular Remodeling of Pulmonary Arterial Hypertension. Am J Respir Cell Mol Biol 54, 384-93
26248159   Curated Info

2

Glading A, et al. (2004) Epidermal growth factor activates m-calpain (calpain II), at least in part, by extracellular signal-regulated kinase-mediated phosphorylation. Mol Cell Biol 24, 2499-512
14993287   Curated Info